Mark Tyson Highlights Key Urology Insights from Journal of Urology
Mark Tyson, Associate Professor of Urology at Mayo Clinic in Arizona, shared on X:
“BCG > gem for LG IR-NMIBC (better RFS); RARC = ORC (RAZOR: no diff in major comps/readmits —>frailty is the key): bilateral > unilateral primary RPLND for stage II seminoma (cuts RP relapse, ~15% crossover). Good stuff in Journal of Urology this month.”
This post by Mark Tyson distills several key findings from the latest Journal of Urology. First, he points to superior recurrence-free survival with BCG over gemcitabine in low-grade, intermediate-risk non–muscle-invasive bladder cancer (LG IR-NMIBC). He then highlights results from the RAZOR trial, showing that robot-assisted radical cystectomy (RARC) and open radical cystectomy (ORC) have comparable complication and readmission rates—emphasizing patient frailty as a crucial factor. Lastly, he notes that bilateral primary retroperitoneal lymph node dissection (RPLND) significantly lowers relapse in stage II seminoma compared to unilateral approaches.
Click the following link to learn more about Bladder Cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023